Arsanis, Inc Announces Series A Financing with OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences

VIENNA - Arsanis, Inc, a recently founded biotechnology company dedicated to the development of anti-infective monoclonal antibody therapeutics, today announced the closing of a Series A financing with a total funding amount of $10 million. Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area. “The current funding will support several pre-clinical proof-of-concept programs that will be the basis for the company’s future development decisions.” The financing involved equal contributions from OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences. Managing Partners, Carl Gordon, Terry McGuire and Mike...